View by Specialty

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

Lymphoma News

SPONSORED CONTENT
Save
SPONSORED CONTENT
January 20, 2022
2 min read
Save

IgG4-related disease linked to increased risk for lymphoma, pancreatic cancer

IgG4-related disease linked to increased risk for lymphoma, pancreatic cancer

Patients with IgG4-related disease are at a higher risk for cancer — particularly pancreatic and lymphoma — compared with the general population, according to a meta-analysis published in Arthritis Research & Therapy.

SPONSORED CONTENT
January 18, 2022
1 min read
Save

Gilead withdraws Zydelig indication for lymphoma, leukemia subtypes

Gilead withdraws Zydelig indication for lymphoma, leukemia subtypes

Gilead Sciences has decided to voluntarily withdraw its accelerated approval of idelalisib for two blood cancer indications.

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

SPONSORED CONTENT
January 14, 2022
1 min read
Save

FDA grants fast track, RMAT designations to bispecific CAR-T for non-Hodgkin lymphoma

FDA grants fast track, RMAT designations to bispecific CAR-T for non-Hodgkin lymphoma

The FDA granted fast track and regenerative medicine advanced therapy designations to C-CAR039, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory diffuse large B cell lymphoma.

SPONSORED CONTENT
January 13, 2022
2 min read
Save

Allogeneic CAR-T induces high response rates in non-Hodgkin lymphoma, B-cell ALL

Allogeneic CAR-T induces high response rates in non-Hodgkin lymphoma, B-cell ALL

An enhanced lymphodepletion regimen followed by chimeric antigen receptor T-cell therapy induced response among patients with relapsed or refractory B-cell malignancies, according to results presented at ASH Annual Meeting and Exposition.

SPONSORED CONTENT
January 11, 2022
1 min read
Save

FDA lifts clinical hold on Allogene’s CAR T-cell therapy trials

FDA lifts clinical hold on Allogene’s CAR T-cell therapy trials

The FDA lifted its clinical hold on a series of trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.

SPONSORED CONTENT
January 06, 2022
3 min read
Save

COVID-19 mortality risk higher among older patients with B-cell malignancies

COVID-19 mortality risk higher among older patients with B-cell malignancies

Older patients with B-cell malignancies diagnosed with COVID-19 had a substantially higher risk for death than their counterparts aged 60 years or younger, according to study results published in JCO Oncology Practice.

SPONSORED CONTENT
January 05, 2022
3 min read
Save

Safety an ‘important differentiating factor‘ for novel CAR-T in B-cell malignancies

Safety an ‘important differentiating factor‘ for novel CAR-T in B-cell malignancies

A chimeric antigen receptor T-cell therapy induced high response rates across a range of B-cell malignancies, according to phase 1 study results presented at ASH Annual Meeting and Exposition.

SPONSORED CONTENT
January 04, 2022
3 min read
Save

COVID-19 vaccine booster dose benefits patients with cancer

COVID-19 vaccine booster dose benefits patients with cancer

Patients with cancer who had no measurable immune response following full COVID-19 vaccination had “excellent potentiation” after receiving a third, booster dose, according to results of a study in Cancer Cell.

SPONSORED CONTENT
January 03, 2022
2 min read
Save

Patients with cancer at high risk for death due to breakthrough COVID-19 infections

Patients with cancer at high risk for death due to breakthrough COVID-19 infections

Fully vaccinated patients with cancer who developed breakthrough COVID-19 infections appeared at high risk for hospitalization and death, according to study results published in Annals of Oncology.

SPONSORED CONTENT
December 30, 2021
2 min read
Save

Residents of low-income, rural areas at higher risk for suicide after cancer diagnosis

Residents of low-income, rural areas at higher risk for suicide after cancer diagnosis

Patients with cancer who resided in low-income and rural areas appeared at higher risk for suicide than those in high-income and urban areas, according to a retrospective, population-based study in JAMA Network Open.

View more